Diabetes

November 18, 2018

Molecular therapy for Obesity-associated metabolic deficits/abnormalities: Mesencephalic astrocyte-derived neurotrophic factor (MANF) may aid in the treatment of TIIDM and obesity-associated metabolic deficits: MANF activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 18/November/2018, 11.33 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]
November 17, 2018

Molecular therapy for blood sugar disease: MANF (Mesencephalic astrocyte-derived neurotrophic factor) increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 17/November/2018, 8.49am

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, the University of Alabama at […]
November 16, 2018

Valproic acid-based therapy for blood sugar disease: Valproic acid  increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 16/October/2018, 11.57 pm

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, the University of Alabama at […]
November 14, 2018

Astrocyte-derived neurotrophic factor comes to the rescue of Diabetes Mellitus: MANF (Mesencephalic astrocyte-derived neurotrophic factor) augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 14/October/2018, 3.38 pm

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]